Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a next-generation somatostatin analog, provides a new...
December 12, 2014 08:30 ET | Source: Novartis Pharma AG

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS

BOLERO-1 trial explored everolimus in women with HER2+ advanced breast cancer and did not meet criteria for statistical significance in first primary objective[1] The second primary objective in...
December 12, 2014 01:15 ET | Source: Novartis Pharma AG

Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin

Cosentyx showed superiority to Stelara®; meeting the primary endpoint of achieving PASI 90, which represents clear or almost clear skin at Week 16 and secondary endpoint of achieving PASI 75 at...
December 08, 2014 13:01 ET | Source: Novartis Pharma AG

Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis

Data from ongoing trial reinforces the safety profile of Jakavi® (ruxolitinib) as seen in previous Phase III studies[1] Patients on Jakavi experienced a reduction in spleen size that was...
December 08, 2014 13:00 ET | Source: Novartis Pharma AG

Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML

Fewer patients on Tasigna vs. Glivec had their leukemia progress to advanced stage, a key goal of treatment in CML and important clinical benefit[1] Patients on Tasigna had higher rates of...
December 08, 2014 01:15 ET | Source: Novartis Pharma AG

Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN®

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast cancer PIONEER data supported filing for biosimilar filgrastim in...
December 06, 2014 13:00 ET | Source: Novartis Pharma AG

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia

Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1] Additionally, sustained remissions were achieved...
December 02, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014

Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia Studies targeting multiple cancer pathways in rare blood...
December 01, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)

Phase III study in primary progressive multiple sclerosis (PPMS) did not meet the primary endpoint PPMS is distinct from other types of MS, with no approved treatment that can change the course...
November 28, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe[1]

Decision by EU review body could speed access to LCZ696 for HFrEF patients in the EU LCZ696 is the first investigational cardiovascular drug to be granted accelerated assessment, shortening...